RXDX - Prometheus Bio and Recursion Pharma on track to post record one-day losses

Mir Basar Suhaib/iStock via Getty Images Recently IPO’ed biotech firms Prometheus Biosciences ([[RXDX]] -21.5%) and Recursion Pharmaceuticals ([[RXRX]] -19.2%) are on course to record their biggest one-day losses since their public debut in March and April, respectively. As demonstrated in the graph, Prometheus has outperformed while Recursion lagged the broader market in the year so far. However, both stocks command bullish views on the Street. Prometheus, which has a very bullish rating among sell-side firms, rose sharply in May in reaction to the news that the stock was added to ARK Genomic Revolution ETF managed by Cathie Wood. Meanwhile, Recursion is likely to end its seven-day winning streak despite yesterday’s announcement on the establishment of a Therapeutics Advisory Board ((TAB)) chaired by the former senior Merck executive Joseph Miletich.

For further details see:

Prometheus Bio and Recursion Pharma on track to post record one-day losses